Tuesday, November 24, 2020

US gives full approval for antiviral remdesivir to treat Covid-19

It can be administered to adults and children over the age of 12 who weigh more than 40kg who require hospitalisation, with emergency approval for its use on paediatric patients under the age of 12 weighing at least 3.5kg.

Other News

476 kes nelayan asing disiasat di bawah Akta Perikanan Pindaan 2019

Kementerian pertanian dan industri makanan perlu melakukan pindaan undang-undang bagi memastikan wilayah perairan negara diperketatkan.

Jangan salah faham, ‘doula’ bukan bidan atau jururawat, kata menteri 

Doula tanpa pendaftaran boleh dikenakan denda RM2,000 atau penjara tidak lebih setahun.

Migration doesn’t threaten Christianity, says pope

Pope Francis says it is 'unacceptable to deter immigration by letting hundreds of migrants die in perilous sea crossings or desert treks'.

UK may remove British judges from Hong Kong court over China’s ‘repression’

London objects to new laws to punish secession, sedition and collusion with foreign forces with up to life in jail.

Govt considering emergency to postpone by-elections in Gerik, Bugaya

Law minister Takiyuddin Hassan says the government is keen to avoid any election to prevent further escalation of Covid-19 cases.

The US Food and Drug Administration (FDA) on Thursday granted full approval to the antiviral drug remdesivir as a treatment for patients hospitalised with Covid-19, after conditional authorisation was given in May.

Gilead said the drug, sold under the brand name Veklury, was the only specific treatment for Covid-19 approved so far under a more rigorous process.

However, other treatments have received authorisation for emergency use, though that approval can be revoked once the public health emergency sparked by the coronavirus pandemic is over.

Other medications, like the steroid dexamethasone, are also being used in the fight against Covid-19.

Gilead’s shares on the New York Stock Exchange jumped 4% soon after the announcement.

“The FDA is committed to expediting the development and availability of Covid-19 treatments during this unprecedented public health emergency,” said FDA commissioner Stephen Hahn.

“Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed and represents an important scientific milestone in the Covid-19 pandemic.”

Europe and other countries such as Canada also have granted temporary approval for the use of remdesivir.

Remdesivir, which is administered by an injection, was one of the first drugs to show relative promise in shortening the time to recovery in some coronavirus patients.

But its efficacy in reducing the mortality rate is unproven.

It can be administered to adults and children over the age of 12 who weigh more than 40kg who require hospitalisation for the treatment of Covid-19, the illness caused by the novel coronavirus.

The drug can only be given to patients in a hospital or equivalent setting.

Emergency approval has been granted for its use on paediatric patients under the age of 12 weighing at least 3.5kg.

President Donald Trump, who tested positive for the coronavirus early in October, was treated with remdesivir at a military hospital outside Washington, among other drugs.

Faster recovery time

The drug was first developed to treat Ebola, a viral hemorrhagic fever.

In February, the US National Institute of Allergy and Infectious Diseases announced it was dusting off remdesivir to investigate against SARS-CoV-2, the pathogen that causes Covid-19, because it had shown promise in animal testing against fellow coronaviruses SARS and MERS.

Its study involving more than 1,000 people, the results of which were released in April, found that patients on the drug had a 31% faster time to recovery than those on a placebo.

Since the medicine is complex to manufacture and is administered via injection, rather than a pill, there have been questions about whether supply could initially be limited.

The US bet early on remdesivir’s success, rushing to preorder nearly all of Gilead’s summer production.

Gilead has set the price at US$390 per vial in developed countries, or US$2,340 for six vials used over the normal five-day course, though US private insurers will pay US$520 per vial.

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Thailand extends emergency for 45 days until mid-January

Thailand's international borders will remain closed to casual travellers.

Record 1,884 new cases, 1,203 in Selangor

Two more deaths take toll to 337.

AstraZeneca, Oxford say Covid vaccine shows 70% efficacy

The 70% average is lower compared with the efficacy of coronavirus vaccines trialled by rivals Pfizer/BioNTech and Moderna which have come in above 90%.

Toronto enters virus lockdown as US looks to vaccine rollout

Toronto has banned private indoor gatherings and capped the size of weddings and funerals for four weeks.

South Korea gets aggressive with third wave ‘in full swing’

'We’re at a critical juncture of facing a large number of infections nationwide.'